Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06356129
Other study ID # CA073-1020
Secondary ID 2023-510178-15U1
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date June 24, 2024
Est. completion date November 20, 2029

Study information

Verified date May 2024
Source Celgene
Contact BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone 855-907-3286
Email Clinical.Trials@bms.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 850
Est. completion date November 20, 2029
Est. primary completion date August 14, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including: i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified [including germinal center B-cell (GCB) and activated B-cell (ABC) types] ii) High-grade B-cell lymphoma, with MYC and BCL2 rearrangements iii) High-grade B-cell lymphoma, not otherwise specified iv) T-cell/histiocyte/rich large B-cell lymphoma (THRLBCL) v) Epstein-Barr virus + DLBCL - International Prognostic Index (IPI) score 1 or 2 with lactate dehydrogenase (LDH) = 1.3 x upper limit of normal (ULN) and/or bulky disease defined as single lesion of = 7 cm OR IPI = 3. - Measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification. - Must have Ann Arbor Stage II-IV disease. Exclusion Criteria: - Any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. - Any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma (PMBCL), primary cutaneous DLBCL-leg type, Grade 3b FL, FL transformed to a-BCL, Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma. - Documented or suspected central nervous system (CNS) involvement by lymphoma. - Other protocol-defined Inclusion/Exclusion criteria apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Golcadomide
Specified dose on specified days
Placebo
Specified dose on specified days
Rituximab
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Doxorubicin
Specified dose on specified days
Vincristine
Specified dose on specified days
Prednisone
Specified dose on specified days

Locations

Country Name City State
Argentina Local Institution - 0112 Buenos Aires
Argentina Local Institution - 0113 Buenos Aires Ciudad Autónoma De Buenos Aires
Argentina Local Institution - 0136 Buenos Aires
Argentina Local Institution - 0421 Buenos Aires Ciudad Autónoma De Buenos Aires
Argentina Local Institution - 0119 Ciudad Autónoma de Buenos Aires
Argentina Local Institution - 0111 Córdoba
Australia Local Institution - 0356 Birtinya Queensland
Australia Local Institution - 0365 Frankston Victoria
Australia Local Institution - 0357 Gosford New South Wales
Australia Local Institution - 0362 Heidelberg Victoria
Australia Local Institution - 0360 Southport Queensland
Australia Local Institution - 0359 St Albans Victoria
Australia Local Institution - 0361 Sydney New South Wales
Australia Local Institution - 0363 Tiwi Northern Territory
Australia Local Institution - 0364 Warrnambool Victoria
Australia Local Institution - 0358 Westmead New South Wales
Austria Local Institution - 0387 Linz
Austria Local Institution - 0386 Vienna
Austria Local Institution - 0385 Wels Oberösterreich
Brazil Local Institution - 0250 Barretos São Paulo
Brazil Local Institution - 0246 Chapecó Santa Catarina
Brazil Local Institution - 0302 Curitiba Paraná
Brazil Local Institution - 0255 Fortaleza Ceará
Brazil Local Institution - 0256 Goiania Goiás
Brazil Local Institution - 0249 Jaú São Paulo
Brazil Local Institution - 0247 Joinville Santa Catarina
Brazil Local Institution - 0297 Lago sul Distrito Federal
Brazil Local Institution - 0304 Natal Rio Grande Do Norte
Brazil Local Institution - 0296 Niteroi Rio De Janeiro
Brazil Local Institution - 0253 Porto Alegre Rio Grande Do Sul
Brazil Local Institution - 0298 Rio de Janeiro
Brazil Local Institution - 0301 São José do Rio Preto São Paulo
Brazil Local Institution - 0248 Sao Paulo São Paulo
Brazil Local Institution - 0252 Sao Paulo São Paulo
Brazil Local Institution - 0316 Sao Paulo São Paulo
Brazil Local Institution - 0251 São Paulo
Brazil Local Institution - 0294 São Paulo
Bulgaria Local Institution - 0393 Plovdiv
Bulgaria Local Institution - 0392 Sofia
Bulgaria Local Institution - 0394 Sofia Sofia (stolitsa)
Canada Local Institution - 0073 Montreal Quebec
Canada Local Institution - 0153 Montreal Quebec
Canada Local Institution - 0004 Sherbrooke Quebec
Canada Local Institution - 0091 Victoria British Columbia
Chile Local Institution - 0109 Chile Región Metropolitana De Santiago
Chile Local Institution - 0106 Santiago Región Metropolitana De Santiago
Chile Local Institution - 0107 Santiago Región Metropolitana De Santiago
Chile Local Institution - 0108 Santiago Región Metropolitana De Santiago
Chile Local Institution - 0110 Santiago Región Metropolitana De Santiago
Chile Local Institution - 0459 Santiago Región Metropolitana De Santiago
Chile Local Institution - 0164 Viña del Mar Valparaíso
China Local Institution - 0334 ??? Liaoning
China Local Institution - 0195 Beijing Beijing
China Local Institution - 0291 Changchun Jilin
China Local Institution - 0275 Changsha Hunan
China Local Institution - 0141 Cheng Du Sichuan
China Local Institution - 0196 Chongqing Chongqing
China Local Institution - 0236 Chongqing Chongqing
China Local Institution - 0274 Fuzhou Fujian
China Local Institution - 0133 Guangzhou Guangdong
China Local Institution - 0240 Guangzhou Guangdong
China Local Institution - 0197 Hangzhou Zhejiang
China Local Institution - 0239 Harbin Heilongjiang
China Local Institution - 0242 Jinan Shandong
China Local Institution - 0344 Jinan Shandong
China Local Institution - 0237 Nanchang Jiangxi
China Local Institution - 0241 Nanchang Jiangxi
China Local Institution - 0338 Nanning Guangxi
China Local Institution - 0132 Shanghai Shanghai
China Local Institution - 0339 Shanghai Shanghai
China Local Institution - 0169 Shenyang Liaoning
China Local Institution - 0156 Suzhou Jiangsu
China Local Institution - 0234 Taiyuan Shanxi
China Local Institution - 0289 Tianjin Tianjin
China Local Institution - 0470 Tianjin Tianjin
China Local Institution - 0155 Urumchi Xinjiang
China Local Institution - 0467 Urumqi Xinjiang
China Local Institution - 0457 Wenzhou Zhejiang
China Local Institution - 0214 Wuhan Hubei
China Local Institution - 0346 Wuhan Hubei
China Local Institution - 0157 Xiamen Fujian
China Local Institution - 0238 Zhengzhou Henan
Colombia Local Institution - 0130 Bogota Cundinamarca
Colombia Local Institution - 0129 Bogotá Distrito Capital De Bogotá
Croatia Local Institution - 0440 Osijek
Croatia Local Institution - 0390 Zagreb Grad Zagreb
Czechia Local Institution - 0105 Brno Brno-mesto
Czechia Local Institution - 0104 Hradec Kralove Hradec Králové
Czechia Local Institution - 0102 Olomouc Olomoucký Kraj
Czechia Local Institution - 0120 Pilsen Plzenský Kraj
Czechia Local Institution - 0103 PRague Praha 10
Czechia Local Institution - 0243 Praha 2
Denmark Local Institution - 0285 Aarhus Midtjylland
Denmark Local Institution - 0284 Odense Syddanmark
Finland Local Institution - 0280 Helsinki
Finland Local Institution - 0283 Kuopio Pohjois-Savo
Finland Local Institution - 0281 Oulu Pohjois-Pohjanmaa
Finland Local Institution - 0282 Turku Varsinais-Suomi
France Local Institution - 0244 Bayonne
France Local Institution - 0090 Bordeaux Aquitaine
France Local Institution - 0332 Brest Finistère
France Local Institution - 0315 Caen
France Local Institution - 0200 Creteil Val-de-Marne
France Local Institution - 0292 Dijon Côte-d'Or
France Local Institution - 0081 Lille Nord
France Local Institution - 0202 Lille
France Local Institution - 0087 Marseille Bouches-du-Rhône
France Local Institution - 0325 Nantes Pays-de-la-Loire
France Local Institution - 0083 Nice Alpes-Maritimes
France Local Institution - 0077 Paris
France Local Institution - 0324 Pessac Aquitaine
France Local Institution - 0089 Pierre-Bénite Rhône
France Local Institution - 0306 Poitiers Vienne
France Local Institution - 0321 Saint Priest en Jarez Loire
France Local Institution - 0335 Saint-Cloud Hauts-de-Seine
France Local Institution - 0323 Saint-Pierre La Réunion
France Local Institution - 0084 Strasbourg Alsace
France Local Institution - 0079 Tours Indre-et-Loire
France Local Institution - 0076 Villejuif Val-de-Marne
Germany Local Institution - 0383 Augsburg Bayern
Germany Local Institution - 0370 Essen
Germany Local Institution - 0384 Koblenz Rheinland-Pfalz
Greece Local Institution - 0398 Alexandroupolis
Greece Local Institution - 0396 Athens Attikí
Greece Local Institution - 0399 Athens Attikí
Greece Local Institution - 0397 Chaidari Attikí
Greece Local Institution - 0395 Ioannina Ípeiros
Hungary Local Institution - 0160 Budapest Pest
Hungary Local Institution - 0163 Budapest
Hungary Local Institution - 0266 Debrecen
Hungary Local Institution - 0162 Kaposvár Somogy
Hungary Local Institution - 0353 Nyiregyhaza Szabolcs-Szatmár-Bereg
Hungary Local Institution - 0161 Szombathely Vas
India Local Institution - 0469 New Delhi Delhi
Japan Local Institution - 0273 Amagasaki Hyogo
Japan Local Institution - 0276 Anjo Aichi
Japan Local Institution - 0350 Bunkyo-ku Tokyo
Japan Local Institution - 0331 Chuo Yamanashi
Japan Local Institution - 0313 Fukuoka
Japan Local Institution - 0319 Fukuoka
Japan Local Institution - 0348 Fukuoka
Japan Local Institution - 0269 Hidaka Saitama
Japan Local Institution - 0328 Himeji Hyogo
Japan Local Institution - 0272 Hiroshima
Japan Local Institution - 0170 Isehara Kanagawa
Japan Local Institution - 0268 Itabashiku Tokyo
Japan Local Institution - 0270 Kanazawa Ishikawa
Japan Local Institution - 0168 Kashiwa Chiba
Japan Local Institution - 0171 Kumamoto
Japan Local Institution - 0215 Kyoto
Japan Local Institution - 0343 Morioka Iwate
Japan Local Institution - 0288 Nagaizumi-cho,Sunto-gun Shizuoka
Japan Local Institution - 0371 Nagoya Aichi
Japan Local Institution - 0271 Ogaki Gifu
Japan Local Institution - 0329 Okayama
Japan Local Institution - 0322 Osaka
Japan Local Institution - 0347 Osaka
Japan Local Institution - 0166 Osaka-sayama Osaka
Japan Local Institution - 0327 Sapporo Hokkaido
Japan Local Institution - 0368 Sapporo Hokkaido
Japan Local Institution - 0320 Sendai-shi Miyagi
Japan Local Institution - 0167 Yamagata
Japan Local Institution - 0333 Yokohama Kanagawa
Korea, Republic of Local Institution - 0114 Busan Pusan-Kwangyokshi
Korea, Republic of Local Institution - 0115 Busan Pusan-Kwangyokshi
Korea, Republic of Local Institution - 0131 Busan Pusan-Kwangyokshi
Korea, Republic of Local Institution - 0442 Daegu Taegu-Kwangyokshi
Korea, Republic of Local Institution - 0116 Deagu Taegu-Kwangyokshi
Korea, Republic of Local Institution - 0149 Goyang-si Kyonggi-do
Korea, Republic of Local Institution - 0117 Seongnam Kyonggi-do
Korea, Republic of Local Institution - 0455 Seongnam
Korea, Republic of Local Institution - 0068 Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Local Institution - 0069 Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Local Institution - 0070 Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Local Institution - 0100 Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Local Institution - 0118 Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Local Institution - 0143 Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Local Institution - 0233 Suwon-si Kyonggi-do
Malaysia Local Institution - 0432 George Town Pulau Pinang
Malaysia Local Institution - 0431 Kuching Sarawak
Mexico Local Institution - 0126 Cdmx Distrito Federal
Mexico Local Institution - 0122 Ciudad de México Distrito Federal
Mexico Local Institution - 0444 Hermosillo Sonora
Mexico Local Institution - 0463 Hermosillo Sonora
Mexico Local Institution - 0123 Huixquilucan
Mexico Local Institution - 0128 México Distrito Federal
Mexico Local Institution - 0121 Mexico City Distrito Federal
Mexico Local Institution - 0139 Monterrey Nuevo León
Mexico Local Institution - 0127 Morelia Michoacán
Mexico Local Institution - 0125 Oaxaca de Juarez Oaxaca
Mexico Local Institution - 0124 Puebla
New Zealand Local Institution - 0462 Auckland
New Zealand Local Institution - 0367 Dunedin Otago
New Zealand Local Institution - 0366 Hamilton Waikato
Norway Local Institution - 0391 Oslo
Poland Local Institution - 0336 Bydgoszcz Kujawsko-pomorskie
Poland Local Institution - 0330 Katowice Slaskie
Poland Local Institution - 0201 Kraków Malopolskie
Poland Local Institution - 0337 Lublin Lubelskie
Poland Local Institution - 0388 Poznan Wielkopolskie
Poland Local Institution - 0443 Warszawa Mazowieckie
Portugal Local Institution - 0286 Lisboa
Portugal Local Institution - 0098 Porto
Puerto Rico Local Institution - 0372 San Juan
Romania Local Institution - 0380 Brasov
Romania Local Institution - 0374 Bucure?ti
Romania Local Institution - 0377 Bucure?ti
Romania Local Institution - 0378 Bucure?ti
Romania Local Institution - 0382 Bucure?ti
Romania Local Institution - 0375 Bucuresti Bucure?ti
Romania Local Institution - 0381 Bucuresti Bucure?ti
Romania Local Institution - 0423 Cluj
Romania Local Institution - 0379 Ia?i
Romania Local Institution - 0376 Sibiu
Romania Local Institution - 0417 Tg.Mures Mure?
Saudi Arabia Local Institution - 0439 Dammam Ash Sharqiyah
Saudi Arabia Local Institution - 0416 Riyadh
Singapore Local Institution - 0427 Singapore Central Singapore
Slovakia Local Institution - 0355 Banska Bystrica Banskobystrický Kraj
Slovakia Local Institution - 0204 Bratislava
Spain Local Institution - 0412 A Coruña A Coruña [La Coruña]
Spain Local Institution - 0389 Barakaldo Bizkaia
Spain Local Institution - 0095 Cáceres
Spain Local Institution - 0409 El Palmar, Murcia Murcia, Región De
Spain Local Institution - 0071 L'Hospitalet Del Llobregat Barcelona [Barcelona]
Spain Local Institution - 0072 Madrid
Spain Local Institution - 0096 Majadahonda Madrid, Comunidad De
Spain Local Institution - 0092 Malaga Málaga
Spain Local Institution - 0093 Salamanca
Spain Local Institution - 0314 San Sebastian Gipuzkoa
Spain Local Institution - 0172 Santa Cruz de Tenerife Canarias
Sweden Local Institution - 0278 Linköping Östergötlands Län [se-05]
Sweden Local Institution - 0277 Uppsala Uppsala Län [se-03]
Taiwan Local Institution - 0142 Chiayi City Chiayi
Taiwan Local Institution - 0159 Kaohsiung
Taiwan Local Institution - 0135 Taichung
Taiwan Local Institution - 0145 Taichung
Taiwan Local Institution - 0146 Tainan City Tainan
Taiwan Local Institution - 0134 Taipei
Taiwan Local Institution - 0147 Taipei
Taiwan Local Institution - 0158 Taoyuan
Thailand Local Institution - 0426 Bangkok Krung Thep Maha Nakhon
Thailand Local Institution - 0434 Bangkok Krung Thep Maha Nakhon
Thailand Local Institution - 0473 Bangkok Krung Thep Maha Nakhon
Thailand Local Institution - 0428 Chiang Mai
Turkey Local Institution - 0400 Ankara
Turkey Local Institution - 0401 Ankara
Turkey Local Institution - 0405 Ankara
Turkey Local Institution - 0422 Ankara
Turkey Local Institution - 0406 Izmir
Turkey Local Institution - 0403 Mersin
Turkey Local Institution - 0407 Samsun
Turkey Local Institution - 0402 Trabzon
United States Local Institution - 0303 Atlanta Georgia
United States Local Institution - 0408 Baton Rouge Louisiana
United States Local Institution - 0190 Buffalo New York
United States Local Institution - 0174 Chapel Hill North Carolina
United States Local Institution - 0182 Chicago Illinois
United States Local Institution - 0461 Des Moines Iowa
United States Local Institution - 0436 Edgewood Kentucky
United States Local Institution - 0031 Fairway Kansas
United States Local Institution - 0435 Fort Sam Houston Texas
United States Local Institution - 0046 Houston Texas
United States Local Institution - 0424 Houston Texas
United States Local Institution - 0287 Jacksonville Florida
United States Local Institution - 0437 Kansas City Missouri
United States Local Institution - 0415 Margate Florida
United States Local Institution - 0066 Massillon Ohio
United States Local Institution - 0067 Minneapolis Minnesota
United States Local Institution - 0014 Mobile Alabama
United States Local Institution - 0049 Morristown New Jersey
United States Local Institution - 0176 New York New York
United States Local Institution - 0369 New York New York
United States Local Institution - 0012 Pensacola Florida
United States Local Institution - 0009 Pittsburgh Pennsylvania
United States Local Institution - 0179 Portland Oregon
United States Local Institution - 0466 Reno Nevada
United States Local Institution - 0293 Richmond Virginia
United States Local Institution - 0203 Rochester Minnesota
United States Local Institution - 0342 San Francisco California
United States Local Institution - 0048 Skokie Illinois
United States Local Institution - 0414 Tampa Florida
United States Local Institution - 0450 Tulsa Oklahoma
United States Local Institution - 0419 York Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Brazil,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Croatia,  Czechia,  Denmark,  Finland,  France,  Germany,  Greece,  Hungary,  India,  Japan,  Korea, Republic of,  Malaysia,  Mexico,  New Zealand,  Norway,  Poland,  Portugal,  Puerto Rico,  Romania,  Saudi Arabia,  Singapore,  Slovakia,  Spain,  Sweden,  Taiwan,  Thailand,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) assessed by the Investigator Up to approximately 67 months
Secondary Overall survival (OS) Up to approximately 67 months
Secondary Event-free survival (EFS) Up to approximately 67 months
Secondary Complete Metabolic Response assessed by the Independent Response Adjudication Committee (IRAC) Up to approximately 18 weeks
Secondary Minimal residual disease (MRD) negativity rate Up to approximately 18 weeks
Secondary Progression-free survival (PFS) assessed by the IRAC Up to approximately 47 months
Secondary Objective response (OR) assessed by the Investigator Up to approximately 18 weeks
Secondary Complete metabolic response (CMR) assessed by the Investigator Up to approximately 18 weeks
Secondary PFS24 assessed by the Investigator 24 months after randomization Up to 24 months
Secondary Duration of response (DoR) Up to approximately 67 months
Secondary Second progression-free survival (PFS2) assessed by the Investigator Up to approximately 67 months
Secondary Relative dose intensity (%) Up to 18 weeks
Secondary Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire Up to approximately 67 months
Secondary Time from randomization to meaningful improvement in primary domains of interest in the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) Questionnaire Up to approximately 67 months
Secondary Mean change from baseline in the EORTC QLQ-C30 Up to approximately 67 months
Secondary Mean change from baseline in the FACT-LymS Up to approximately 67 months
Secondary Number of participants with Adverse Events (AEs) Up to approximately 20 weeks
Secondary Number of participants with treatment-emergent adverse events (TEAEs) Up to approximately 20 weeks
Secondary Number of participants with laboratory abnormalities Up to approximately 20 weeks
Secondary Number of participants with vital sign abnormalities Up to approximately 20 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT05929716 - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT05464719 - A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Phase 2
Recruiting NCT06047080 - An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Phase 3
Active, not recruiting NCT04566978 - 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) Early Phase 1
Recruiting NCT06104592 - Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Phase 2
Recruiting NCT04889716 - CAR-T Followed by Bispecific Antibodies Phase 2
Recruiting NCT04250324 - Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma Phase 1
Recruiting NCT05326243 - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT05794958 - Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Phase 1
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Phase 1
Recruiting NCT05404048 - PD-L1 PET-imaging During CAR T-cell Therapy Phase 2
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT06375733 - A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL Phase 1/Phase 2
Recruiting NCT05887167 - Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Phase 1
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Recruiting NCT05643742 - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Phase 1/Phase 2
Recruiting NCT05820841 - Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma Phase 3
Recruiting NCT05472610 - Study of Efficacy of BZ019 in Large B-cell Lymphoma Phase 2
Recruiting NCT03960840 - Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL Phase 1/Phase 2
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1